Pfizer said its Q3 2024 revenues totaled $17,702 million, up 31% from $13,491 million a year earlier, and rose 32% on an operational basis, excluding the effect of foreign exchange.

1. 01

   Pfizer said its Q3 2024 revenues totaled $17,702 million, up 31% from $13,491 million a year earlier, and rose 32% on an operational basis, excluding the effect of foreign exchange.

2. 02

   The company said Paxlovid revenues for Q3 2024 were $2.7 billion, up $2.5 billion on an operational basis from the year-earlier quarter, and that the one-time delivery to the U.S. Strategic National Stockpile contributed $442 million of that revenue.

3. 03

   Pfizer raised its full-year revenue guidance to $61.0 to $64.0 billion (previously $59.5 to $62.5 billion) and its Adjusted diluted EPS guidance to $2.75 to $2.95 (previously $2.45 to $2.65), the company said.

4. 04

   Pfizer said it sold 640 million Haleon ordinary shares to institutional investors and 60.5 million Haleon shares directly to Haleon in October 2024, receiving total net consideration of about $3.5 billion, and that its ownership stake fell from about 23% to about 15%.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.